



Collaboration. Acceleration. Results.



The Myelin Repair Foundation Enters First International Partnership with Bionure, Inc.

Bionure, Inc. and Myelin Repair Foundation Collaboration to Advance Neuroprotective Multiple Sclerosis (MS) Therapeutic BN201 Towards Commercialization

SARATOGA, CA and BARCELONA, Spain—October, 31, 2013 —The [Myelin Repair Foundation](#) (MRF) and [Bionure, Inc.](#) today entered a collaborative partnership agreement to advance therapeutics development for Multiple Sclerosis (MS). The Foundation's unique [Accelerated Research Collaboration™ \(ARC™\) model](#) facilitates collaboration between the top MS leaders worldwide to advance promising compounds into the clinic. In this agreement, the Myelin Repair Foundation will work closely with Bionure, Inc. to assess the neuroprotective capabilities that will promote myelin repair of the company's proprietary MS therapeutic compound, BN201.

Through this unique partnership, Bionure, Inc. will collaborate with MRF researchers at the Myelin Repair Foundation's Translational Medicine Center, an industry-standard laboratory facility dedicated to the evaluation of promising myelin repair candidates for MS. At the laboratory, MRF scientists with extensive biopharma experience moving therapeutic compounds into the clinic will assess Bionure's BN201 for its neuroprotective properties to enhance remyelination. BN201 is a potential MS treatment for acute optic neuritis and severe MS relapses.

"We are excited to partner with the Myelin Repair Foundation to advance our compound closer to the clinic," said CEO Albert G. Zamora at Bionure, Inc. "With the top scientific expertise and innovative myelin repair research tools and assays at the MRF, this partnership will accelerate our progress towards addressing the unmet needs of MS patients."

"In our world-wide search for innovative MS companies, Bionure is an ideal partner for us, given their unique approach to treat MS," said [Chief Research Officer Dr. Jay Tung, Ph.D.](#) at the Myelin Repair Foundation. "By leveraging our non-profit status to collaborate with global innovative MS companies such as Bionure, our strategy is to investigate and advance many promising MS compounds towards commercialization."

The Myelin Repair Foundation's rigorous, industry-leading [Translational Medicine Platform](#) ensures comprehensive scientific validation of potential therapeutics for MS clinical trials. Dr. Stephen Hauser, from University of California, San Francisco, one of the world's leading authorities on neurology and a member of President of Barack Obama's Bioethics Committee. Dr. Lawrence Steinman from Stanford University is also an advisory board member at Bionure, Inc.

About the Myelin Repair Foundation

The Myelin Repair Foundation (MRF) (www.myelinrepair.org) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair

therapeutics for Multiple Sclerosis. Its [Accelerated Research Collaboration™](#) (ARC™) model is designed to optimize the process of medical research, drug development and the delivery of new patient treatments.

About Bionure, Inc.

Bionure, Inc. (www.bionure.com) is a Silicon Valley and Barcelona based early stage drug development company focused on developing neuroprotective therapies for the treatment of neurodegenerative diseases. Bionure will enter into the clinic for Acute Optic Neuritis/Neuromyelitis Optica in 2014 (Orphan drug designation).

Contact for Media Inquiries:

Jennifer Chang
Director of Communications
The Myelin Repair Foundation
jchang@myelinrepair.org
408-871-2410